What is Oncotarget?

Ontotarget is an online database that features bio-medical journals that are peer-reviewed at least twice weekly. The Chief editors, Mikhail Blagosklonny and Andrei V. Gudkov have monitored the site since 2010. Scientists or ordinary viewers can enjoy a variety of articles that focus on sub-topics of Oncology including aging, Microbiology, Virology, Immunology and more.

Working towards Better Cancer Treatment

Based on new research published by Oncotarget, there’s a small protein modification that stimulates migratory and invasive properties of prostate cancer cells. This new finding helps scientists understand the movement of the cancer cells from on area to another and can lead to the development of more effective therapies. Listen to an audio podcast of Oncotarget on Itunes.

Background

Metastatic tumors stem from individuals breaking free from a tumor and traveling to an unwanted location. These can further develop into secondary tumors. The prostate cancer cells mentioned in the study mainly travels through epithelial-to-mesenchymal transition (EMT) activated by growth factor known as TGFB (transforming growth factor beta). However, unwanted proteins such as Snail1 gets activated in the process, creating complications in the body. Listen to Oncotarget podcast on Player.FM.

Research Findings

Researchers from two Swedish Universities were able to determine the following information about the role and modification of Snail1:

– Sumoylation, the process of modifying the amino acids (building blocks) of Snail1, can reduce its effects and make cancer cells more invasive.

– Snail1 induces TGFB signaling and EMT in prostate cancer.

– In patients with prostate cancer, they have elevated levels of Snail1.

Although it is uncertain whether Snail1 is the main cause of prostate cancer, sumoylating the protein can combat the cancer and possibly breast cancer tumors.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Understanding More About Clay Siegall

His years of experience in the specialization of cancer therapies date back to 1988 when he joined the National Cancer Institute and the National Institutes of Health until 1991. He later spent six years at the Bristol-Myers Squibb Pharmaceutical Research Institute before he left to start the Seattle Genetics. Clay B. Siegall, Ph.D., is the CEO and Chairman of the Board. Seattle Genetics is an organization whose foundation is based on scientific innovation, arduous research, best drug development practices, and a passionate urge to help others.

 

The death of Dr. Siegall’s father with cancer inspired him to utilize the basic tools available to oncologists in finding better ways of helping cancer patients. After pursuing a doctorate at George Washington University and earning enough experience in three institutes that natured his passion for cancer therapy, he was well prepared to launch the Seattle Genetics Company. For over thirty years, he has been waking up daily excited and passionate about going around helping cancer patients.

 

Under the innovative leadership of Dr. Siegall, the FDA approved a collaborative effort by Takeda Pharmaceutical Company and Seattle Genetics for developing Antibody-Drug Conjugates (ADCs) in 2011 named ADCETRIS® (brentuximab vedotin). The drug has become an international brand. Seattle Genetics has made several advancements in creating ADCs that have proved vital in the fight against cancer.

 

Under his guidance, the organization has partnered with Genentech, AbbVie, and GlaxoSmithKline among other licenses in generating $300 million. Several ADCs are still utilizing the Seattle Genetics’ technology to experiment on other clinical developments. Through the Initial Public Offer (IPO) of 2001 and public financing, Dr. Siegall has enabled the organization to secure a capital of about $1.2 billion.

 

He is a member of the board of directors of various organizations such as the Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and the Washington Roundtable. He has also received various awards during his practice like the 2013 University of Maryland Alumnus of the Year for Computer and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. His skills have made a great impact in generating 15 patents and publishing 70 research reports.